A novel use of temozolomide in a patient with malignant prolactinoma.
We report a 64-year-old male who presented to our department in 2007 with bitemporal hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and metastatic deposits elsewhere in his neuraxis. He underwent a transphenoidal excision of the large pituitary adenoma which was uncomplicated, although he did suffer from diabetes insipidus post-operatively. He had initially been diagnosed with prolactinoma some years before and had undergone multiple craniotomies to debulk recurrent metastatic lesions. As the patient had already undergone radiotherapy in the past, a novel approach to adjuvant therapy was necessary and he was started on a course of oral chemotherapy, temozolomide, with good results.
Byrne
Stephen
S
Department of Neurosurgery, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia 5042, Australia. stephentbyrne@hotmail.com
Karapetis
Chris
C
Vrodos
Nick
N
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D015175:Prolactinoma / Q000188:drug therapy*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide